



## **ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference**

January 6, 2026

WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- **ProKidney Corp. (Nasdaq: PROK)** ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that ProKidney's CEO, Bruce Culleton, M.D., will present at the 44<sup>th</sup> Annual J.P. Morgan Healthcare Conference. The ProKidney management team will also host one-on-one meetings throughout the event.

### **44<sup>th</sup> Annual J.P. Morgan Healthcare Conference**

*Date:* Wednesday, January 14, 2026

*Time:* 8:15am PST

*Format:* Presentation

*Webcast:* [Link](#)

The live webcast will also be accessible through the "Events" section of the Investor Relations tab within ProKidney's website at [www.prokidney.com](http://www.prokidney.com). Following the completion of the event, a replay will be available for 30 days.

### **About ProKidney Corp.**

ProKidney, a pioneer in the treatment of CKD through innovations in cell therapy, was founded in 2015 after a decade of research. ProKidney's lead product candidate, rilparencel (also known as REACT<sup>®</sup>), is a first-in-class, patented, proprietary autologous cell therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit [www.prokidney.com](http://www.prokidney.com).

### **ProKidney Contact**

Ethan Holdaway

[Ethan.Holdaway@prokidney.com](mailto:Ethan.Holdaway@prokidney.com)

### **Media Contact**

Audra Friis

[audrafriis@sambrown.com](mailto:audrafriis@sambrown.com)

### **Investor Relations Contact**

Daniel Ferry

[Daniel@lifesciadvisors.com](mailto:Daniel@lifesciadvisors.com)